## DEXTROMETHORPHAN with QUINIDINE

| Generic | Brand | HICL | GCN | Exception/Other |
|---|---|---|---|---|
| DEXTROMETHORPHAN/ QUINIDINE | NUEDEXTA | 37278 | | |

### GUIDELINES FOR USE

1. Does the patient have a diagnosis of pseudobulbar affect (PBA)?

   If yes, **approve for 12 months by HICL for #2 per day per month.**
   If no, do not approve.
   **DENIAL TEXT:** Our guideline for **DEXTROMETHORPHAN with QUINIDINE** requires a diagnosis of pseudobulbar affect (PBA).

### RATIONALE
Ensure that Nuedexta is used solely for its FDA approved indication and in patients for whom it has been determined to be safe and efficacious.

### FDA APPROVED INDICATION
Nuedexta is indicated for treatment of pseudobulbar affect (PSA).

### REFERENCES

- Avanir Pharmaceuticals, Inc. Nuedexta package insert. Aliso Viejo, CA. January 2015.
- Miller A, Pratt H, and Schiffer R. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011; 11(7) 1077-1088:
- National Stroke Association. Pseudobulbar affect and stroke. Stroke Clinical Updates. Volume XV, Issue 1: January/February 2005.
- Pioro E. Current concepts in pharmacotherapy of pseudobulbar affect. Drugs 2004; 71 (9): 1192-1207.


| Library | Commercial | NSA |
|---|---|---|
| Yes | Yes | No |

Part D Effective: N/A
Commercial Effective: 05/01/15
Created: 02/11
Client Approval: 03/15
P&T Approval: 01/15